Leuprolide acetate given by a subcutaneous extended-release injection: less of a pain?
| Autor: | Charity D. Scripture, Michael C. Cox, William D. Figg |
|---|---|
| Rok vydání: | 2005 |
| Předmět: |
Male
medicine.medical_specialty Antineoplastic Agents Hormonal Injections Subcutaneous Pain Pharmacology Drug Administration Schedule Dosage form Androgen deprivation therapy Subcutaneous injection Prostate cancer Leuprorelin Internal medicine medicine Humans Pharmacology (medical) Testosterone Clinical Trials as Topic business.industry Prostatic Neoplasms medicine.disease Endocrinology Oncology Delayed-Action Preparations Drug delivery Hormonal therapy Leuprolide business medicine.drug |
| Zdroj: | Expert Review of Anticancer Therapy. 5:605-611 |
| ISSN: | 1744-8328 1473-7140 |
| Popis: | Androgen deprivation therapy is a mainstay for the treatment of advanced prostate cancer. Hormonal therapy commonly consists of injection of gonadotropin hormone-releasing hormone agonists. Based on the need for improved convenience of administration, a novel formulation of leuprolide acetate (Eligard; Atrix Laboratories Inc. & Sanofi Aventis) which incorporates a mixture of selected polymers and solvents to achieve sustained drug delivery after subcutaneous injection, was developed. The US Food and Drug Administration has approved 1-, 3-, 4- and 6-month formulations of leuprolide acetate. In clinical trials, leuprolide acetate achieves sustained suppression of serum testosterone to castration levels (< or =50 ng/dl). The adverse-event profile is consistent with the effects of testosterone suppression. This novel delivery system in addition to the availability of a 6-month formulation of leuprolide acetate, offers patients the option of a convenient twice-yearly injection schedule. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|